Johnson & Johnson (JNJ)

Industry Drug Manufacturers - General
This stock can be held in an Investment ISA and an Investment Account
Sell

$151.00

Buy

$151.10

arrow-up$1.72 (+1.15%)

Prices updated at 17 May 2025, 00:58 EDT
| Prices minimum 15 mins delay
|
Prices in USD
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices segments.
S&P 500
arrow-up0.7%
NYSE
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Drug Manufacturers - General
Chairman
Mr. Timothy Schmid
CEO
Mr. Joaquin Duato
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
139,800
Head office
One Johnson & Johnson Plaza
New Brunswick
United States
08933
mobile
+1 732 524-0400
letter
investor-relations@its.jnj.com
computer
Company website

Key personnel

Owner name
chevron-l-regular
chevron-r-regular
Salary
Mr. Darius E. Adamczyk
Independent Director
0.13m
Ms. Anne M. Mulcahy
Independent Director
0.17m
Dr. John C. Reed,M.D.,PhD
Executive Vice President, Innovative Medicine, R&D
1.19m
Ms. Marillyn A. Hewson
Lead Independent Director
0.18m
Dr. Paula A. Johnson,M.D.
Independent Director
0.13m
Mr. Hubert Joly
Independent Director
0.13m
Dr. Mary C. Beckerle, PhD
Independent Director
0.15m
Dr. Mark B. McClellan, M.D.,PhD
Independent Director
0.13m
Mr. Joaquin Duato
Chairman of the Board and Chief Executive Officer
1.60m
Dr. Jennifer A. Doudna, PhD
Independent Director
0.13m
Mr. Joseph J. Wolk, C.P.A.
Executive Vice President and Chief Financial Officer
1.21m
Mr. James D. Swanson
Executive Vice President and Chief Information Officer
-
Ms. Jennifer L. Taubert
Executive Vice President and Worldwide Chairman, Innovative Medicine
1.19m
Ms. Kathryn E. Wengel
Executive Vice President and Chief Technical Operations & Risk Officer
-
Mr. Eugene A. Woods
Independent Director
0.13m
Dr. Nadja Y. West, M.D.
Independent Director
0.13m
Mr. Mark A. Weinberger
Independent Director
0.15m
Mr. Robert J. Decker, Jr
Controller and Chief Accounting Officer
-
Ms. Vanessa Broadhurst
Executive Vice President, Global Corporate Affairs
-
Ms. Elizabeth Forminard
Executive Vice President and Chief Legal Officer
-
Mr. Timothy Schmid
Executive Vice President and Worldwide Chairman, MedTech
0.90m
Ms. Kristen Mulholland
Executive Vice President and Chief Human Resources Officer
-

Top 5 shareholders

Owner name
chevron-l-regular
chevron-r-regular
No. of shares
Vanguard Group Inc233,962,679
BlackRock Inc199,366,959
State Street Corp134,456,157
Vanguard Investments Australia Ltd77,490,082
BlackRock Fund Advisors76,904,097

Director dealings

Date
chevron-l-regular
chevron-r-regular
Action
30 Apr 2024-
12 Dec 2024-
10 Dec 2024-
10 Dec 2024-
10 Sep 2024-
10 Sep 2024-
30 Aug 2024-
30 Aug 2024-
30 Aug 2024-
08 Jul 2024-
08 Jul 2024-
08 Jul 2024-
04 Jun 2024-
04 Jun 2024-
17 Oct 2024-
17 Oct 2024-
22 May 2024-
01 May 2024-
01 May 2024-
01 May 2024-
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.